Source:http://linkedlifedata.com/resource/pubmed/id/10813152
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2000-5-23
|
| pubmed:abstractText |
Failure to seroconvert (primary vaccine failure) is believed to be the principal reason (approx. > 95%) why some vaccinees remain susceptible to measles and is often attributed to the persistence of maternal antibodies in children vaccinated at a young age. Avidity testing is able to separate primary from secondary vaccine failures (waning and/or incomplete immunity), but has not been utilized in measles epidemiology. Low-avidity (LA) and high-avidity (HA) virus-specific IgG antibodies indicate primary and secondary failure, respectively. Measles vaccine failures (n = 142; mean age 10.1 years, range 2-22 years) from an outbreak in 1988-9 in Finland were tested for measles-virus IgG avidity using a protein denaturating EIA. Severity of measles was recorded in 89 failures and 169 non-vaccinees (mean age 16.2 years, range 2-22 years). The patients with HA antibodies (n = 28) tended to have clinically mild measles and rapid IgG response. Among failures vaccinated at < 12, 12-15 and > 15 months of age with single doses of Schwarz-strain vaccine in the 1970s, 50 (95% CI 1-99), 36 (CI 16-56) and 25% (CI 8-42) had HA antibodies, respectively. When a single measles, mumps and rubella (MMR) vaccine had been given after 1982 at 15 months of age, only 7% (CI 0-14) showed HA antibodies. Omitting re-vaccinees and those vaccinated at < 15 months, Schwarz-strain recipients had 3.6 (CI 1.1-11.5) higher occurrence of HA responses compared to MMR recipients. Apart from one municipality, where even re-vaccinees had high risk of primary infection, 89% (CI 69 to approximately 100) of the infected re-vaccinees had an HA response. Secondary measles-vaccine failures are more common than was more previously thought, particularly among individuals vaccinated in early life, long ago, and among re-vaccinees. Waning immunity even among individuals vaccinated after 15 months of age, without the boosting effect of natural infections should be considered a relevant possibility in future planning of vaccination against measles.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0950-2688
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
124
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
263-71
|
| pubmed:dateRevised |
2010-3-3
|
| pubmed:meshHeading |
pubmed-meshheading:10813152-Adolescent,
pubmed-meshheading:10813152-Adult,
pubmed-meshheading:10813152-Age Distribution,
pubmed-meshheading:10813152-Age Factors,
pubmed-meshheading:10813152-Antibodies, Viral,
pubmed-meshheading:10813152-Antibody Specificity,
pubmed-meshheading:10813152-Child,
pubmed-meshheading:10813152-Child, Preschool,
pubmed-meshheading:10813152-Disease Outbreaks,
pubmed-meshheading:10813152-Female,
pubmed-meshheading:10813152-Finland,
pubmed-meshheading:10813152-Humans,
pubmed-meshheading:10813152-Immunoglobulin G,
pubmed-meshheading:10813152-Male,
pubmed-meshheading:10813152-Measles,
pubmed-meshheading:10813152-Measles Vaccine,
pubmed-meshheading:10813152-Time Factors,
pubmed-meshheading:10813152-Treatment Failure,
pubmed-meshheading:10813152-Vaccination
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.
|
| pubmed:affiliation |
Department of Public Health, University of Helsinki, Finland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|